# Pharmacokinetics and Safety of Single-Dose Wafermine™ (Ketamine Sublingual Wafer) in Healthy Subjects

> **NCT07691372** · PHASE1 · NOT_YET_RECRUITING · sponsor: **iX Biopharma Ltd.** · enrollment: 14 (estimated)

## Conditions studied

- Healthy Adult Participants

## Interventions

- **DRUG:** Wafermine™ (ketamine sublingual wafer)

## Key facts

- **NCT ID:** NCT07691372
- **Lead sponsor:** iX Biopharma Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-09
- **Primary completion:** 2026-07-17
- **Final completion:** 2026-07-17
- **Target enrollment:** 14 (ESTIMATED)
- **Last updated:** 2026-07-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07691372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07691372, "Pharmacokinetics and Safety of Single-Dose Wafermine™ (Ketamine Sublingual Wafer) in Healthy Subjects". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07691372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*